FierceBiotech 2 juin 2026 ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech 2 juin 2026 ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
FierceBiotech 2 juin 2026 MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
FierceBiotech 2 juin 2026 Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
FierceBiotech 2 juin 2026 ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data
FierceBiotech 1 juin 2026 ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
FierceBiotech 1 juin 2026 Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
FierceBiotech 1 juin 2026 Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
FierceBiotech 1 juin 2026 Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
FierceBiotech 1 juin 2026 Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
FierceBiotech 1 juin 2026 Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
FierceBiotech 31 mai 2026 ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout